Forte Biosciences (NASDAQ:FBRX - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.09), FiscalAI reports.
Forte Biosciences Price Performance
Shares of Forte Biosciences stock traded down $0.09 during midday trading on Wednesday, hitting $76.78. 1,915,118 shares of the company were exchanged, compared to its average volume of 600,512. The firm has a market cap of $1.07 billion, a P/E ratio of -16.55 and a beta of 2.62. Forte Biosciences has a 52 week low of $9.91 and a 52 week high of $77.20. The firm has a 50 day simple moving average of $39.65 and a 200-day simple moving average of $31.86.
Institutional Trading of Forte Biosciences
A number of large investors have recently bought and sold shares of the stock. Global Retirement Partners LLC bought a new position in shares of Forte Biosciences during the fourth quarter valued at $27,000. Bank of America Corp DE boosted its position in Forte Biosciences by 5,641.8% in the third quarter. Bank of America Corp DE now owns 3,158 shares of the company's stock valued at $47,000 after buying an additional 3,103 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Forte Biosciences in the third quarter valued at about $161,000. Jane Street Group LLC bought a new stake in Forte Biosciences during the fourth quarter worth about $228,000. Finally, Citadel Advisors LLC bought a new stake in Forte Biosciences during the third quarter worth about $234,000. 77.63% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research firms have weighed in on FBRX. Barclays downgraded shares of Forte Biosciences from an "overweight" rating to an "equal weight" rating and lifted their price target for the stock from $74.00 to $77.00 in a research note on Tuesday, July 28th. TD Cowen downgraded shares of Forte Biosciences from a "strong-buy" rating to a "hold" rating in a report on Monday, July 27th. Wall Street Zen downgraded shares of Forte Biosciences from a "sell" rating to a "strong sell" rating in a report on Saturday, July 25th. Weiss Ratings lowered shares of Forte Biosciences from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, July 28th. Finally, Evercore set a $77.00 target price on shares of Forte Biosciences in a research note on Monday, July 27th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $72.50.
Check Out Our Latest Stock Analysis on FBRX
About Forte Biosciences
(
Get Free Report)
Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.
The company's lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Forte Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Forte Biosciences wasn't on the list.
While Forte Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
